Search results for "Globin"

showing 10 items of 734 documents

Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia.

1998

The radiosensitivity of solid tumours in anaemic rats treated with recombinant human erythropoietin (rhEPO, epoetin beta) was studied. Anaemia was induced by a single dose of carboplatin (45 mg kg(-1) i.v.), resulting in a reduction in the haemoglobin concentration by 30%. In a second group, the development of anaemia was prevented by rhEPO (1000 IU kg(-1)) administered s.c. three times per week starting 6 days before the carboplatin application. Three days after carboplatin treatment, DS-sarcomas were implanted subcutaneously onto the hind foot dorsum. Neither carboplatin nor rhEPO treatment influenced tumour growth rate. Five days after implantation, tumours were irradiated with a single …

MaleCancer Researchmedicine.medical_specialtyAnemiamedicine.medical_treatmentUrologyAntineoplastic AgentsRadiation ToleranceCarboplatinRats Sprague-Dawleychemistry.chemical_compoundHemoglobinsInternal medicinemedicineAnimalsHumansRadiosensitivityErythropoietinEpoetin betaChemotherapybusiness.industryAnemiamedicine.diseaseCarboplatinRecombinant ProteinsRatsRadiation therapyEndocrinologyOncologychemistryErythropoietinToxicitySarcoma ExperimentalbusinessNeoplasm Transplantationmedicine.drugResearch ArticleBritish journal of cancer
researchProduct

Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: An 8-month prospective pi…

2015

Objective: To explore the effects of the glucagon-like peptide-1 receptor analogue liraglutide on subclinical atherosclerosis in diabetic subjects with non-alcoholic fatty liver disease (NAFLD).Research design and methods: In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years). Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.Main outcome measures: Anthropometric variables, glucometabolic parameters and carotid intima-media thickness (IMT) using B-mode …

MaleClinical BiochemistryPilot ProjectsType 2 diabetesCarotid Intima-Media ThicknessGastroenterologychemistry.chemical_compoundRisk FactorsDrug DiscoveryProspective StudiesProspective cohort studyliraglutideMedicine (all)Fatty liverLipidMiddle AgedLipidsHemoglobin AAtherosclerosiFemalemedicine.drugHumanmedicine.medical_specialtycarotid intima-media thickneInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsPilot ProjectAgedGlycated HemoglobinHemoglobin A GlycosylatedPharmacologytype 2 diabeteHypoglycemic AgentLiraglutidebusiness.industryRisk FactorDrug Discovery3003 Pharmaceutical Sciencenutritional and metabolic diseasesnon-alcoholic fatty liver diseaseAtherosclerosismedicine.diseaseProspective StudieEndocrinologychemistryIntima-media thicknessDiabetes Mellitus Type 2Glycated hemoglobinbusiness
researchProduct

Influence of intracellular convection on the oxygen release by human erythrocytes

1972

There is general agreement today that intracellular diffusive transport of HbO2 and O2 limits the rate of oxygen uptake or release by the blood in the exchange vessels. Recent hemorheological results have shown that the mammalian erythrocyte exhibits fluidity as its most unique rheological property: it can be deformed continuously and rapidly, shear and normal stresses can be transmitted to the interior of the cell where systems of laminar flow are induced. These mechanical properties lead to the question whether or not intracellular convection does take place in the erythrocyte and to what extent it plays a part in gas exchange. A method was developed which subjects oxygen-saturated soluti…

MaleConvectionErythrocytesTime FactorsPhysiologyPartial PressureClinical BiochemistryAnalytical chemistryErythrocytes Abnormalchemistry.chemical_elementOxygenMicrocirculationDiffusionHemoglobinsRheologyOsmotic PressurePhysiology (medical)HumansRed CellChemistryCell MembraneTemperatureBiological TransportLaminar flowPartial pressureBlood ViscosityBody FluidsOxygenBiophysicsFemaleRheologyIntracellularPfl�gers Archiv European Journal of Physiology
researchProduct

Type 2 diabetes and cognitive impairment in an older population with overweight or obesity and metabolic syndrome: baseline cross-sectional analysis …

2018

This study cross-sectionally examines in the elderly population: (a) the association of type 2 diabetes with executive function (EF); (b) the effect of BMI on both type 2 diabetes and EF; (c) the association between glycaemia control and EF in type 2 diabetes. 6823 older individuals with overweight/obesity and metabolic syndrome participating in the PREDIMED-PLUS study, were assessed with a battery of cognitive tests and a medical interview. ANOVA showed a significantly worse performance on EF in type 2 diabetes vs. non-diabetic individuals. Two complementary models were displayed: (1) in the whole sample, the presence of type 2 diabetes, depressive symptoms and BMI had a direct negative ef…

MaleCross-sectional studyhumanosType 2 diabetesOverweightPersones gransBody Mass Index0302 clinical medicineOlder people diseasesMedicine030212 general & internal medicineDiabetes Treatment AdherenceCognitive declineMalalties de les persones gransmediana edad2. Zero hungerMetabolic SyndromeancianoMultidisciplinaryDiabetisCognitive ageingQDiabetesRType 2 diabetesMiddle Aged3. Good healthNeurologydiabetes mellitusMedicineObesitatFemalemedicine.symptomPREDIMEDmedicine.medical_specialtyMedicinaScienceArticle03 medical and health sciencesOlder populationDiabetes mellitusInternal medicineApnoeaHumansCognitive DysfunctionObesityobesidadAgedGlycated Hemoglobinbusiness.industryíndice de masa corporalBaseline Cross-sectional AnalysisCognitive neuroscienceCognitive Function PerformanceOverweightmedicine.diseaseObesityCross-Sectional StudiesDiabetes Mellitus Type 2StudyMetabolic syndromeOlder peoplebusinessBody mass index030217 neurology & neurosurgeryestudios transversalesGlycaemic Control
researchProduct

Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison

2015

AimsImproving glycaemic control in people with Type1 diabetes is known to reduce complications. Our aim was to compare glycaemic control among people with Type1 diabetes using data gathered in regional or national registries. MethodsData were obtained for children and/or adults with Type1 diabetes from the following countries (or regions): Western Australia, Austria, Denmark, England, Champagne-Ardenne (France), Germany, Epirus, Thessaly and Thessaloniki (Greece), Galway (Ireland), several Italian regions, Latvia, Rotterdam (The Netherlands), Otago (New Zealand), Norway, Northern Ireland, Scotland, Sweden, Volyn (Ukraine), USA and Wales) from population or clinic-based registries. The sampl…

MaleDenmarkEndocrinology Diabetes and Metabolismmetabolic-controlregistryEndocrinologyGermanyInsulinMedicineadolescentsRegistriesYoung adultNetherlandseducation.field_of_studyGreeceNorway18 countriesClinical PracticeEnglandItalyAustriaPractice Guidelines as TopicFemaleFranceGuideline AdherenceUkraineAdultcomplicationsAdolescentPopulationNorthern IrelandNorthern irelandAge and sexYoung AdultInsulin Infusion SystemschildrenDiabetes mellitusInternal MedicineHumansHypoglycemic AgentscareeducationchildhoodGlycated HemoglobinSwedenType 1 diabetesWalesbusiness.industryWestern Australiamedicine.diseaseLatviaiddmUnited StatesDiabetes Mellitus Type 1ScotlandSample size determinationOptometrybusinessIrelandNew ZealandDemographyDiabetic Medicine
researchProduct

Potential influence of Type A personality on plasma C-reactive protein levels in people with diabetes

2016

IF 4.693; Aim. Type A personality, although classically known as a factor linked to increased vascular risk, has recently been associated with increased survival in patients with diabetes. As low-grade inflammation predicts a poor outcome, the present study explored the potential associations between Type A and plasma levels of C-reactive protein (CRP) in diabetes. Methods. Type A personality was assessed by the Bortner questionnaire in people with diabetes. The association between Type A and plasma CRP levels was examined by multivariable linear regression, and structural equation modelling (SEM) was performed to determine the impact of the major clinical, biological and psychological conf…

MaleEndocrinology Diabetes and Metabolism[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionType 2 diabetesBody Mass Index0302 clinical medicineEndocrinologyc-reactive proteinWeight lossself-care030212 general & internal medicineProspective cohort studymedia_common2. Zero hungerbiologydiabetesGeneral Medicine[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismMiddle Aged[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismanxiety3. Good healthFemalemedicine.symptomweight-lossAdultmedicine.medical_specialtymedia_common.quotation_subjectprospective cohort030209 endocrinology & metabolism03 medical and health sciencesInternal medicineDiabetes mellitus[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyInternal MedicinemedicineHumansPersonalityAgedGlycated Hemoglobintype abusiness.industrybehaviorC-reactive proteinassociationType A PersonalityType A and Type B personality theorymedicine.disease5-factor modelmortalityEndocrinologyDiabetes Mellitus Type 2personalityinflammationbiology.proteinbusinesscoronary-heart-disease[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass index[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Presence of calreticulin mutations in JAK2-negative polycythemia vera

2014

Abstract Calreticulin (CALR) mutations have recently been reported in JAK2- and MPL-negative Myeloproliferative Neoplasms (MPN), particularly essential thrombocythemia (ET) and primary myelofibrosis (PMF).The clinical course of sporadic CALR-mutated patients seems to be more indolent than that of JAK2-mutated patients. In contrast, no CALR mutation has been found in the 647 published cases of Polycythemia Vera (PV) patients tested. Consequently, CALR mutations were considered exclusive to JAK2 and MPL mutations. Since 98% of PV patients harbor a JAK2 mutation (mostly the V617F mutation in exon 14 and more rarely, in exon 12), the absence of CALR mutations in PV seemed logical. Here, we desc…

MaleErythrocytesMESH: Thrombocytosismedicine.disease_causeMESH: Polycythemia VeraBiochemistryMESH: Janus Kinase 2MESH: GenotypeHemoglobinsMESH: Aged 80 and overPolycythemia verahemic and lymphatic diseasesPolycythemia VeraMESH: HeterozygoteAged 80 and overThrombocytosisMESH: AgedMutation[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyJanus kinase 2biologyMESH: ErythrocytesExonsHematologyLeukemiaMESH: HemoglobinsMESH: Primary MyelofibrosisThrombocythemia EssentialHeterozygoteMESH: MutationGenotypeMESH: CalreticulinImmunologyContext (language use)medicineHumansMyelofibrosisAllelesAgedMESH: HumansEssential thrombocythemiabusiness.industryMESH: AllelesCell BiologyJanus Kinase 2medicine.diseaseMESH: MalePrimary MyelofibrosisMESH: Gene DeletionMutationImmunologybiology.proteinCancer researchMESH: Thrombocythemia EssentialCalreticulinMESH: ExonsbusinessCalreticulinGene Deletion[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBlood
researchProduct

Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits.

2018

Abstract Marketed formulations of erythropoietin (EPO) ior®EPOCIM, MIRCERA® and two newly developed pegylated-EPO analogues (PEG-EPO 32 and 40 kDa) formulations were intravenously administered to New Zealand rabbits. A semi-mechanistic Pharmacokinetic/Pharmacodynamic (PK/PD) model describing in a simultaneous and integrated form the time course of reticulocytes, red blood cells and hemoglobin was built to account for the time course of hematopoiesis stimulation after erythropoietin administration. Data analysis was performed based on the population approach with the software NONMEM version 7.3. Erythropoietin disposition of each of the administered formulations was best described with a two…

MaleErythrocytesReticulocytesDrug CompoundingPopulationPharmaceutical ScienceBiological AvailabilityPharmacology030226 pharmacology & pharmacyModels BiologicalPolyethylene Glycols03 medical and health sciencesHemoglobins0302 clinical medicinePharmacokineticshemic and lymphatic diseasesMedicineAnimalseducationErythropoietinVolume of distributioneducation.field_of_studybusiness.industryRecombinant ProteinsNONMEMHematopoiesisHaematopoiesisErythropoietin030220 oncology & carcinogenesisPharmacodynamicsInjections IntravenousHematinicsLinear ModelsHemoglobinRabbitsbusinessmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Optimization of anemia treatment in hemodialysis patients via reinforcement learning

2013

Objective: Anemia is a frequent comorbidity in hemodialysis patients that can be successfully treated by administering erythropoiesis-stimulating agents (ESAs). ESAs dosing is currently based on clinical protocols that often do not account for the high inter- and intra-individual variability in the patient's response. As a result, the hemoglobin level of some patients oscillates around the target range, which is associated with multiple risks and side-effects. This work proposes a methodology based on reinforcement learning (RL) to optimize ESA therapy. Methods: RL is a data-driven approach for solving sequential decision-making problems that are formulated as Markov decision processes (MDP…

MaleFOS: Computer and information sciencesMathematical optimizationDarbepoetin alfaComputer scienceAnemiaComputer Science - Artificial Intelligencemedicine.medical_treatmentMedicine (miscellaneous)Machine Learning (stat.ML)Outcome (game theory)Decision Support TechniquesMachine Learning (cs.LG)Renal DialysisArtificial IntelligenceStatistics - Machine LearningmedicineHumansReinforcement learningDosingAgedProtocol (science)Patient SelectionAnemiaHemoglobin AMiddle Agedmedicine.diseaseMarkov ChainsComputer Science - LearningArtificial Intelligence (cs.AI)Chronic DiseaseHematinicsKidney Failure ChronicFemaleHemodialysisMarkov decision processReinforcement PsychologyAlgorithmsmedicine.drug
researchProduct

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-…

2017

Background Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes. Methods DEPICT-1 was a double-blind, randomised, parallel-controlled, three-arm, phase 3, multicentre study done at 143 sites in 17 countries. Eligible patients were aged 18–75 years and had inadequately controlled type 1 diabetes (HbA1c between ≥7·7% and ≤11·0% [≥61·0 mmol/mol and ≤97·0 mmol/mol]) and had been prescribed insulin for at least 12 months before enrolment. After an 8 week lead-in period to optimise diabetes man…

MaleGlycated Hemoglobin AEndocrinology Diabetes and MetabolismType 2 diabetes030204 cardiovascular system & hematologySettore MED/13 - Endocrinologialaw.inventionchemistry.chemical_compound0302 clinical medicineEndocrinologydiabetes dapaglifozinGlucosidesRandomized controlled triallawInsulin03.02. Klinikai orvostanDapagliflozinMiddle AgedDiabetes and MetabolismTreatment OutcomeCombinationDrug Therapy CombinationFemaleType 1Adultmedicine.medical_specialtyDiabetic ketoacidosis030209 endocrinology & metabolismPlacebo03 medical and health sciencesDrug TherapyDiabetes managementDiabetes mellitusInternal medicineDiabetes MellitusInternal MedicinemedicineHumansHypoglycemic AgentsBenzhydryl CompoundsAdult; Benzhydryl Compounds; Body Weight; Diabetes Mellitus Type 1; Drug Therapy Combination; Female; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment OutcomeAdult; Benzhydryl Compounds; Body Weight; Diabetes Mellitus Type 1; Drug Therapy Combination; Female; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome; Internal Medicine; Endocrinology Diabetes and Metabolism; EndocrinologyGlycated HemoglobinType 1 diabetesbusiness.industryBody Weightmedicine.diseaseHypoglycemiaSurgeryDiabetes Mellitus Type 1chemistrybusinessThe Lancet Diabetes & Endocrinology
researchProduct